This drug could halve death risk from most common type of lung cancer

An already-available drug shows evidence of helping to increase the survival rate in patients with EGRF mutations of non-small cell lung cancer. — AFP

A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumour, according to clinical trial results presented on June 4 (2023).

The results were unveiled in Chicago, United States, at the largest annual conference of cancer specialists, hosted by the American Society for Clinical Oncology (ASCO).